PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

French Riviera Still a Buyer's Market According to New Figures

The number of real estate transactions taking place on the French Riviera continued to fall in 2013 leading to lower prices across much of the region.

French Riviera Still a Buyer's Market According to New Figures
2014-04-12
CANNES, FRANCE, April 12, 2014 (Press-News.org) According to the Alpes Maritimes' branch, FNAIM 06, the number of French Riviera property sales fell by 10% in 2013; the figure is an improvement on 2012 when sales in the region were down nearly 15%.

Drops in real estate prices have been seen across the French Riviera, the average price per square metre in Nice in the last quarter of 2013 was 4,134 euros compared to 4,293 euros in 2012.

Cannes and Antibes saw similar reductions with the average price in 2013 at 4,634 euros and 4,460 euros respectively per square metre.

Of course in the fashionable French Riviera there are always exceptions and some of the fashionable resorts on the coast reported a slight rise.

Philip Weiser of luxury property brokers Carlton International said that "the general economic situation in France together with the fiscal uncertainty, is responsible for the temporary decline in transactions and corresponding decline in prices."

The fall in demand for South of France property over recent years leading to lower prices is sure to give savvy investors untold opportunities, especially at the top end of the market. Weiser, who has over 30 years experience in luxury property investment said "these opportunities are rare in prime areas such as London, New York, Paris and the French Riviera. Historically, such opportunities occurred from 1982 to 1985, 1991 to 1994 and now, beginning in 2011."

He also urged investors to look at the market trends for these periods saying "historically, this period is not unlimited in time and the cycle will soon end. Now is the time to invest in the knowledge that values of properties bought at market value tend to double every ten years in normal times but inflate disproportionately after difficult times."

On the Cote d'Azur the limited capacity for additional construction has restricted the over-building seen in many parts of the world. Demand, both for primary and secondary residences has, more often than not, exceeded supply and this is a trend we are likely to see return.

Carlton International shared more good news for those seeking luxury property in the South of France; "The result in a weak market is that an owner wishing to sell within a given period is obliged to be competitive in terms of price. Furthermore, it is evident that homes which sell in these circumstances are generally better prepared for the market and in better condition."

The reticence of the banking institutions to lend to the French primary home market during awkward times can make it difficult to obtain a loan for French citizens. For non French investors, the banks are more adaptable, given the secondary home nature of the investments made by foreign buyers, who often have no need for financing, other than to offset any French Wealth Tax liability.

Despite the downturn in prices, there will always be property owners who need to sell due to a variety of circumstances, be it for work, financial or family commitments. This is all good news for those buyers who are new to the market in the South of France and in particular for foreign investors.

ABOUT CARLTON INTERNATIONAL

Carlton International is a prestigious real-estate agency based in the South of France. Our experienced consultants consistently negotiate French property transactions at the highest end of the market earning us a reputation as specialists in luxury French Riviera property sales and rentals. We offer a discreet service allowing our wealthy customers the privacy required for such transactions.

For those looking to purchase luxury property on the French Riviera, Carlton International can assist you in your search. Carlton International represents some of the most exclusive property for sale in the south of France. St. Tropez, Cap D'Antibes, Cap Ferrat and Cannes real estate are all available to be viewed through the website at www.carlton-international.com.

[Attachments] See images for this press release:
French Riviera Still a Buyer's Market According to New Figures

ELSE PRESS RELEASES FROM THIS DATE:

Extreme Weather Alert: Revolutionary New Dry Skin Cream Soars Above Accepted Industry Standard

2014-04-12
How well do dry skin care lotions fare against each other when tested for the ability to keep one's skin moisturized, especially during our constantly changing weather conditions? A new study, which included the shielding lotion Skin MD Natural had surprising results according to Germaine Muniz at Cantor Research Laboratories. Cantor Research Laboratories discovered that when Skin MD Natural skin lotion treatment was applied to dry skin, it actually increased the skin's ability over time to retain moisture. All other products tested, including Vaseline Petroleum Jelly ...

Hepatitis C treatment cures over 90 percent of patients with cirrhosis

2014-04-12
SAN ANTONIO, Texas (April 12, 2014) — Twelve weeks of an investigational oral therapy cured hepatitis C infection in more than 90 percent of patients with liver cirrhosis and was well tolerated by these patients, according to an international study that included researchers from UT Medicine San Antonio and the Texas Liver Institute. Historically, hepatitis C cure rates in patients with cirrhosis (liver scarring) have been lower than 50 percent and the treatment was not safe for many of these patients. Hepatitis C virus is the No. 1 driver of cirrhosis, liver transplants ...

Obeticholic acid produces meaningful biochemical and clinical improvements in PBC cirrhosis patients

2014-04-12
London, UK, Saturday 12 April 2014: Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, or have been unable to tolerate ursodeoxycholic acid (UDCA), produced meaningful biochemical and clinical improvements. UDCA is the only therapy currently approved to treat PBC. Obeticholic acid at both a 10 mg dose and a 5 mg dose titrated to 10 mg, met the trial's primary composite endpoint ...

Three new studies help clarify optimal use of combination therapy in chronic hepatitis B patients

2014-04-12
London, UK, Saturday 12 April 2014: Three new studies presented today at the International Liver CongressTM 2014 have helped clarify the optimal use of combination therapy with peginterferon and nucleoside analogues (NUCs) to achieve the best treatment outcomes in patients with chronic hepatitis B (CHB). "Together these ground-breaking data will go a long way to influencing future CHB treatment guidelines," said EASL's Educational Councillor Professor Cihan Yurdaydin from the Department of Gastroenterology, University of Ankara, Turkey. In the first study , CHB patients ...

New Chinese herbal medicine has significant potential in treating hepatitis C

2014-04-12
London, UK, Saturday 12 April 2014: Data from a late-breaking abstract presented at the International Liver CongressTM 2014 identifies a new compound, SBEL1, that has the ability to inhibit hepatitis C virus (HCV) activity in cells at several points in the virus' lifecycle.[i] SBEL1 is a compound isolated from Chinese herbal medicines that was found to inhibit HCV activity by approximately 90%. SBEL1 is extracted from a herb found in certain regions of Taiwan and Southern China. In Chinese medicine, it is used to treat sore throats and inflammations. The function of SBEL1 ...

Impressive SVR12 data for once-daily combination to treat HCV genotype 1 patients

2014-04-12
London, UK, Saturday 12 April 2014: Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ledipasvir (LDV) 90mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection have been presented at the International Liver CongressTM 2014. "With cure rates well in excess of 90% with as little as eight weeks of treatment for some patients, these data represent ...

Gut microbiota may play a role in the development of alcoholic liver disease

2014-04-12
London, UK, Saturday 12 April 2014: Exciting new data presented today at the International Liver Congress™ 2014 shows that the gut microbiota has a potential role in the development of alcoholic liver disease (ALD).1 Though an early stage animal model, the French study highlights the possibility of preventing ALD with faecal microbiota transplantation – the engrafting of new microbiota, usually through administering human faecal material from a healthy donor into the colon of a recipient.2 In the study, two groups of germ-free mice received gut microbiota transplants ...

Low vitamin D linked to fatty liver disease in UK children

2014-04-12
London, UK, Saturday 12 April 2014: A UK study[i] investigating the link between low vitamin D status and non-alcoholic fatty liver disease (NAFLD) in British children has identified a genetic variant associated with the disease's severity. The research, conducted by the King's College Hospital Paediatric Liver Centre and the University of Surrey's School of Biosciences and Medicine, and funded by the Children's Liver Disease Foundation retrospectively analysed the medical records of 120 paediatric patients with NAFLD. The findings could carry significant implications ...

New advances in HCC diagnosis, staging and treatment all predicted to improve patient outcomes

2014-04-12
London, UK, Saturday 12 April 2014: Epidemiological, genetic and clinical data presented today at the International Liver CongressTM 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment of hepatocellular carcinoma (HCC). "Human hepatocellular carcinoma is one of the most prevalent cancers worldwide and the second most frequent cause of cancer-related death," said EASL's Scientific Committee Member Dr Helen Reeves Senior Lecturer & Honorary Consultant Gastroenterologist at Newcastle Hospitals NHS Foundation Trust, ...

New interferon-free, all-oral 3D regimen achieves high SVR in chronic HCV genotype 1 patients

2014-04-12
London, UK, Saturday 12 April 2014: The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented today at the International Liver CongressTM 2014. The 3D regimen consists of the HCV NS3/4A protease inhibitor ABT-450 dosed with ritonavir, the NS5A inhibitor ABT-267, and the NS5B RNA polymerase inhibitor ABT-333. "Using this investigational ...

LAST 30 PRESS RELEASES:

New superconductor with hallmark of unconventional superconductivity discovered

Global HIV study finds that cardiovascular risk models underestimate for key populations

New study offers insights into how populations conform or go against the crowd

Development of a high-performance AI device utilizing ion-controlled spin wave interference in magnetic materials

WashU researchers map individual brain dynamics

Technology for oxidizing atmospheric methane won’t help the climate

US Department of Energy announces Early Career Research Program for FY 2025

PECASE winners: 3 UVA engineering professors receive presidential early career awards

‘Turn on the lights’: DAVD display helps navy divers navigate undersea conditions

MSU researcher’s breakthrough model sheds light on solar storms and space weather

Nebraska psychology professor recognized with Presidential Early Career Award

New data shows how ‘rage giving’ boosted immigrant-serving nonprofits during the first Trump Administration

Unique characteristics of a rare liver cancer identified as clinical trial of new treatment begins

From lab to field: CABBI pipeline delivers oil-rich sorghum

Stem cell therapy jumpstarts brain recovery after stroke

Polymer editing can upcycle waste into higher-performance plastics

Research on past hurricanes aims to reduce future risk

UT Health San Antonio, UTSA researchers receive prestigious 2025 Hill Prizes for medicine and technology

Panorama of our nearest galactic neighbor unveils hundreds of millions of stars

A chain reaction: HIV vaccines can lead to antibodies against antibodies

Bacteria in polymers form cables that grow into living gels

Rotavirus protein NSP4 manipulates gastrointestinal disease severity

‘Ding-dong:’ A study finds specific neurons with an immune doorbell

A major advance in biology combines DNA and RNA and could revolutionize cancer treatments

Neutrophil elastase as a predictor of delivery in pregnant women with preterm labor

NIH to lead implementation of National Plan to End Parkinson’s Act

Growth of private equity and hospital consolidation in primary care and price implications

Online advertising of compounded glucagon-like peptide-1 receptor agonists

Health care utilization and costs for older adults aging into Medicare after the affordable care act

Reading the genome and understanding evolution: Symbioses and gene transfer in leaf beetles

[Press-News.org] French Riviera Still a Buyer's Market According to New Figures
The number of real estate transactions taking place on the French Riviera continued to fall in 2013 leading to lower prices across much of the region.